Abiopharma

(10% Negative) REGENERON PHARMACEUTICALS, INC. (REGN) Reports Q4 2025 Financial Results

(99% Positive) TENET HEALTHCARE CORP (THC) Reports Q4 2025 Financial Results

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

Tenet Reports Strong Third Quarter 2025 Results; Raises 2025 Financial Outlook

(19% Negative) GeneDx Holdings Corp. (WGSWW) Reports Q4 2025 Financial Results

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Regeneron Reports Third Quarter 2025 Financial and Operating Results

New Form 6-K - Genenta Science S.p.A. Filed: 2025-10-28 AccNo: 0001493152-25-019808 Size: 349 KB

New Form 6-K - NOVARTIS AG Filed: 2025-10-28 AccNo: 0001114448-25-000003 Size: 1 MB

(10% Negative) Vivani Medical, Inc. (VANI) Announces Delay in agent Development Timeline Due to Safety Review, Efficacy Assessment

Zymeworks Announces Participation in Upcoming Investor Conferences

Rockwell Medical to Exhibit at ASN Kidney Week 2025